---
layout: default
title: Sulfamethoxazole
parent: Moderate Evidence (L3-L4)
nav_order: 738
evidence_level: L4
indication_count: 1
---

# Sulfamethoxazole
{: .fs-9 }

Evidence Level: **L4** | Predicted Indications: **1** 
{: .fs-6 .fw-300 }

---

## Table of Contents
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## Pharmacist Assessment Report

</div>

# Sulfamethoxazole: From Bacterial Infections to Acute Contagious Conjunctivitis

## One-Sentence Summary

> Sulfamethoxazole is a sulfonamide antibacterial agent; its specific original indication record is a data gap, but its drug class is well established for treating bacterial infections.
> The TxGNN model predicts it may be effective for **Acute Contagious Conjunctivitis**,
> with **0 clinical trials** and **1 publication** currently supporting this direction — evidence remains preliminary.

---

## Quick Overview

| Item | Content |
|------|------|
| Original Indication | Not available — drug is not marketed in Canada (0 licenses); known only as a sulfonamide antibacterial by drug class |
| Predicted New Indication | Acute Contagious Conjunctivitis |
| TxGNN Prediction Score | 99.63% |
| Evidence Level | L4 |
| Canada Market Status | ✗ Not Marketed |
| Number of DINs | 0 |
| Recommended Decision | Hold |

---

## Why is This Prediction Reasonable?

Detailed mechanism-of-action data for this drug is not formally recorded (MOA field: data gap). However, supporting evidence indicates sulfamethoxazole is a sulfonamide antibiotic that competitively inhibits dihydropteroate synthase, blocking the bacterial folate synthesis pathway. This gives it broad-spectrum antibacterial activity against common conjunctivitis pathogens such as *H. influenzae*, *S. pneumoniae*, and *S. aureus*.

The relationship between the (unrecorded) original indication and the predicted new indication is plausible on class grounds: sulfamethoxazole belongs to the sulfonamide family, and a related compound, sulfacetamide, is already used as a topical ophthalmic agent for bacterial conjunctivitis. This provides a reasonable mechanistic bridge between systemic antibacterial use and a localized ocular infection indication.

That said, the TxGNN score (99.63%) primarily reflects a knowledge-graph mechanistic association rather than direct clinical evidence. Before this prediction can be taken further, basic drug-level data gaps — particularly the missing original indication and the unclear reason for non-marketing status in Canada — should be resolved.

---

## Clinical Trial Evidence

Currently no related clinical trials registered.

---

## Literature Evidence

| PMID | Year | Type | Journal | Key Findings |
|------|-----|------|------|---------|
| [31788487](https://pubmed.ncbi.nlm.nih.gov/31788487/) | 2019 | Observational (cross-sectional microbiology survey) | Medical Hypothesis, Discovery & Innovation Ophthalmology Journal | Retrospective analysis of childhood acute bacterial conjunctivitis in Western Greece, characterizing causative bacteria and antimicrobial susceptibility patterns relevant to empiric antibiotic selection |

---

## Canada Market Information

Sulfamethoxazole currently has no marketing authorization (DIN) in Canada, and no product license records are available in this dataset.

---

## Safety Considerations

Please refer to the package insert for safety information. Note: regulatory label warnings/contraindications (TFDA equivalent) are flagged as a **Blocking** data gap (DG001), meaning this candidate cannot yet enter the S1 safety pre-assessment stage.

---

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
Evidence is limited to a single observational (non-RCT) publication with no clinical trials, and the underlying drug-level data — including original indication, MOA, and regulatory safety warnings — has critical gaps, one of which (TFDA label warnings/contraindications) is blocking. The candidate cannot proceed past S0 until these are resolved.

**To proceed, the following is needed:**
- TFDA (or equivalent) product label warnings and contraindications (DG001 — blocking)
- Confirmed mechanism of action via DrugBank API query (DG002)
- Original indication record for this drug
- Clarification of Canada non-marketing status
- Evaluation of route compatibility (ophthalmic formulation availability), currently pending
- Additional clinical or RCT-level evidence specific to sulfamethoxazole (or its combinations) in bacterial conjunctivitis
## Disclaimer

This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.

---

